REMEDI - The Regenerative Medicine Institute at the National University of Ireland Galway
The Regenerative Medicine Institute (REMEDI) is a Science Foundation Ireland-funded research centre focused on using stem cell and regenerative medicine technologies to treat human disease. Recognised as Ireland leading stem cell research centre, REMEDIs mission is to conduct basic research in stem cell biology and to translate and commercialize the results to regenerative therapeutics. Based at the National University of Ireland Galway, REMEDI is a collaboration between scientists, engineers, clinicians and industry.
REMEDI currently has focused research programmes in areas such as stem cell biology, immunology, gene therapy and cell manufacturing and the two main translational targets at the centre are vascular disease and osteoarthritis. To fulfil its translational mission, REMEDI manages and operates the Centre for Cell Manufacturing Ireland (CCMI), a facility licensed by the Irish Medicines Board to manufacture stem cells for human applications.
Researchers at REMEDI have to date coordinated three European Framework Programme 7-funded projects (Purstem, Reddstar and Visicort) and have partnered on four more (Gamba, Adipoa, Eurostemcell and Decide).
REMEDI researchers have ongoing projects with approximately 25 companies including Medtronic Vascular, Eli Lilly, De Puy and Miltenyi. Orbsen Therapeutics is a spin out company from REMEDI which has developed proprietary technologies (ORB1) that enables the isolation of pure and therapeutic stromal cells from human tissues.
Since its foundation in 2004 REMEDI scientists have published over 250 original journal articles, given over 330 invited talks, filed 13 patents, won 47 scientific awards, been cited over 12,500 times and graduated 110 Masters and 36 PhD students.
